Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.80 | N/A | +0.63% |
management commentary, guidance changes, and full analysis available with Pro.
Boston Scientific Co (BSX) is a leading medical device company that develops and manufactures a wide range of products for various medical fields, including cardiology, urology, and endoscopy. As a key player in the health care sector, the company's innovations help improve patient outcomes and drive advancements in medical technology.
Earnings Per Share (EPS)
EPS is a critical measure of the company's profitability and will indicate how well Boston Scientific is managing costs and generating income.
Revenue Growth
Revenue growth is essential to understand the demand for Boston Scientific's products and overall market performance.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
| +0.63% |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on operational performance. They emphasized the importance of innovation and customer engagement.
Management highlighted strong demand in key product areas.
They expressed confidence in maintaining market share despite challenges.
Boston Scientific's strong EPS performance suggests effective cost management and possibly robust sales in certain segments, leading to an 8.99% increase in stock price. The market reacted positively, reflecting investor confidence in the company's ability to navigate challenges. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Boston Scientific Co (BSX) is a leading medical device company that develops and manufactures a wide range of products for various medical fields, including cardiology, urology, and endoscopy. As a key player in the health care sector, the company's innovations help improve patient outcomes and drive advancements in medical technology.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+5.92%
Avg Stock Reaction
+0.45%
In the last quarter, Boston Scientific reported an EPS of $0.80, exceeding expectations by nearly 3%. However, the stock experienced a significant drop of 17.59% the following day, indicating market concerns despite the positive earnings surprise.
Management Promises & Guidance
Overall, Wall Street seems cautiously optimistic about Boston Scientific's upcoming earnings, given its history of beating EPS estimates. However, there are concerns about potential revenue growth and market dynamics.
Bull Case
The optimistic view hinges on strong demand for new products and continued market share gains, which could lead to better-than-expected revenue and EPS growth.
Bear Case
Conversely, if revenue growth falls short or if there are signs of increased competition, the stock could face downward pressure, especially given the recent volatility.
Earnings Per Share (EPS)
N/AEPS is a critical measure of the company's profitability and will indicate how well Boston Scientific is managing costs and generating income.
Revenue Growth
N/ARevenue growth is essential to understand the demand for Boston Scientific's products and overall market performance.
Market Share in Key Segments
N/ATracking market share in specific medical device segments will help gauge the company's competitive position and growth potential.
The print will turn on these two things.
Q1
What is the revenue growth rate for new product lines?
This will indicate how well Boston Scientific is capturing market demand and expanding its footprint in key therapeutic areas.
Q2
How is the company addressing competitive pressures in its core markets?
Understanding the company's strategy to maintain or grow market share will be crucial for assessing future performance.
Why consensus could be wrong
The Street may be underestimating the impact of Boston Scientific's recent product launches, which could drive higher-than-expected revenue growth despite competitive pressures.
Supporting Evidence
The company's historical EPS beat rate of 88% suggests a strong track record of exceeding expectations.
Options pricing indicates a significant expected move, which may reflect heightened uncertainty rather than a negative outlook.
Recent product innovations have received positive feedback from healthcare providers, indicating strong market demand.
Key Risk
If revenue growth exceeds 10%, it could challenge the current bearish sentiment and shift market expectations.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to sustain growth amid competitive pressures and market dynamics.
Bull Confirmed If
Revenue growth of 10% or more, indicating strong demand for new products and successful market penetration.
Bear Confirmed If
Revenue growth below 5%, suggesting potential challenges in maintaining market share or demand.
Implied Move
±8.34%
Historical Avg
±5.3%
The options market is pricing in a significant move of over 8% in either direction, reflecting uncertainty about the upcoming earnings report.
Options are pricing ±8.3% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Boston Scientific beats expectations and raises guidance, history suggests the stock could see a positive reaction, averaging a 4.85% increase on such outcomes.
In-Line / Cautious
An in-line report with cautious commentary may lead to muted market reactions, as investors assess the implications for future growth.
Miss
If the company misses expectations, history suggests a potential decline of around 5.68%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ZIONS BANCORP N A
Apr 20, 2026